Dissolution and liquidation of 日本和心醫藥有限公司
First written in FY2023-Q1. 1 of 3 entries say "Restated". Latest entry: FY2024.
The whole theme swung hardest in 2024: 2 of 11 companies on the "Worse" side.
35 other companies' latest entry also says "Achieved".
- FY2024AchievedAnnual report
「日本和心醫藥有限公司 was excluded from the scope of consolidation because its liquidation was completed during the fiscal year.」
The dissolution and liquidation of 日本和心醫藥有限公司, resolved in December 2022, was completed in May 2024. - FY2024-Q1RestatedAnnual report
「At a board meeting held on 21 December 2022, the company resolved to dissolve and liquidate its consolidated subsidiary 日本和心醫藥有限公司 (head office: Hong Kong; chair: Nagasawa Kazuchu (長沢和宙)). As of the date of filing this report, the company is proceeding with the necessary procedures in accordance with local laws and regulations.」
The dissolution and liquidation procedures for the Hong Kong subsidiary were still under way as of the filing date of this quarterly report. - FY2023-Q1First statedAnnual report
「At a board meeting held on 21 December 2022, the company resolved to dissolve and liquidate its consolidated subsidiary 日本和心醫藥有限公司 (head office: Hong Kong; chair: Nagasawa Kazuchu (長沢和宙)). As of the date of filing this report, the company is proceeding with the necessary procedures in accordance with local laws and regulations.」
A resolution was passed to dissolve and liquidate the consolidated subsidiary located in Hong Kong, and procedures under local law were under way as of the filing date.